Antennova

Antennova Marks Milestone in Cancer Treatment with Promising Early Results from Anti-CD24 Antibody Trial

DOYLESTOWN, PA — In a significant stride toward advancing cancer treatment, Antennova, a clinical-stage biotechnology firm dedicated to oncology, has announced the successful completion of the first dosing cohort in …

Antennova Marks Milestone in Cancer Treatment with Promising Early Results from Anti-CD24 Antibody Trial Read More

Annovis Bio

Annovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data Cleaning

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a biotech firm focused on developing novel treatments for neurodegenerative diseases, announced the successful completion of data cleaning for its pivotal phase …

Annovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data Cleaning Read More

Ocugen

Ocugen’s Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon

MALVERN, PA — Ophthalmology is on the crest of a wave; a paradigm shift heralded by Ocugen, Inc (NASDAQ: OCGN) may be imminent. The Pennsylvania-based biopharmaceutical firm recently crossed a …

Ocugen’s Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon Read More

Larimar Therapeutics

Larimar Therapeutics Advances Nomlabofusp Clinical Program with First Patient Dosed in Open Label Extension Study

BALA CYNWYD, PA — Clinical-stage biotechnology company Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced the dosing of the first patient in an open label extension (OLE) study for its novel …

Larimar Therapeutics Advances Nomlabofusp Clinical Program with First Patient Dosed in Open Label Extension Study Read More